Sonography-guided Pericapsular Never Group Block for Hip Arthroplasty (QUASH)

September 10, 2020 updated by: Xiangcai Ruan, MD, PhD, Vice-Director in Dept Anesth & Pain, Guangzhou First People's Hospital

Sonography-guided Pericapsular Nerve Group Block for Hip Arthroplasty

In this study, the investigator will examine the efficacy of Pericapsular nerve group (PENG) block in hip arthroplasty as a post-operative pain management technique, study the analgesia, opioid-sparing effects and motor-blocking effects of the PENG block

Study Overview

Status

Unknown

Detailed Description

PENG Block group (PG) will receive 0.5%Ropivacaine in 20 ml of saline. Sham Block group (SG) will receive 20 ml of saline Patient will be sedated with IV midazolam before nerve block. After peripheral nerve block ,general anesthesia will be conducted using sufentanyl, propofol and rocuronium for induction and propofol and sevoflurane for maintenance. Tests will be operated after procedure,and recorded up to 48 hours after surgery.

Study Type

Interventional

Enrollment (Anticipated)

71

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510180
        • Recruiting
        • Guangzhou First Municipal People's Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xiangcai Ruan, MD, PHD
        • Sub-Investigator:
          • Jun Zheng, MD, Msc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients scheduled for hip arthroplasty

Exclusion Criteria:

  • allergy to local anesthetics
  • infection at the injection site
  • patients receiving opioids for chronic analgesic therapy
  • other lower limb neuropathies
  • inability to comprehend visual analog scale (VAS)
  • preexist cognitive dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pericapsular nerve group block
Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
Placebo Comparator: Saline placebo group
Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Highest VAS score in recovery room
Time Frame: before recovery room discharge(up to 2 hours after surgery end)
Highest VAS score reported in recovery room,patient will be asked questions to measure the highest VAS score experienced in the recovery room before discharge. If the patient had a unexpected long stay at recovery room, the question will be asked at the time point "2 hours after surgery end"
before recovery room discharge(up to 2 hours after surgery end)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
VAS at rest
Time Frame: day0 ,day1 ,day2
VAS pain score while patient at rest
day0 ,day1 ,day2
highest VAS at period
Time Frame: day0 ,day1 ,day2
highest VAS reported at follow up period
day0 ,day1 ,day2
quadriceps strength
Time Frame: day0 , day1 ,day2
Measure quadriceps strength peak value at different time point
day0 , day1 ,day2
total opioid consumption
Time Frame: up to 2 days after surgery
up to 2 days after surgery
PONV rate
Time Frame: day0 ,day1 ,day2
postoperative nausea and vomit
day0 ,day1 ,day2
Fall incident happened
Time Frame: up to 2 days after surgery
Record the fall incident happened,fall is defined as patinent accidently fall to the ground.
up to 2 days after surgery
Nerve block range
Time Frame: day0 , before discharge from PACU(up to 2 hours after surgery end)
A cotton yarn with ethanol will be put on both the surgical and nonsurgical leg to evaluate the cold sensation lost after nerve block.Skin sensation lost will be tested at lateral thigh,medial thigh,front thigh and lateral claf
day0 , before discharge from PACU(up to 2 hours after surgery end)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 10, 2020

Primary Completion (Anticipated)

March 31, 2021

Study Completion (Anticipated)

March 31, 2021

Study Registration Dates

First Submitted

July 2, 2020

First Submitted That Met QC Criteria

July 16, 2020

First Posted (Actual)

July 21, 2020

Study Record Updates

Last Update Posted (Actual)

September 14, 2020

Last Update Submitted That Met QC Criteria

September 10, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Analgesia

Clinical Trials on pericapsular nerve group block

3
Subscribe